Ironwood Pharmaceuticals, Inc. Class A
As of Oct 22, 2026, Ironwood Pharmaceuticals is in Stage 3, the topping phase, now in week 3 (since Oct 6, 2026). It closed at $3.57, 33.8% below its 52-week high and below its 200-day average, which is rising.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is IRWD early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
IRWD among Drug Manufacturers - Specialty & Generic4th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
Ironwood Pharmaceuticals: quick answers
What stage is Ironwood Pharmaceuticals in?
As of Oct 22, 2026, Ironwood Pharmaceuticals (IRWD) is in Stage 3, the topping phase. It entered Stage 3 on Oct 6, 2026 and is in week 3. What the four stages mean
Is Ironwood Pharmaceuticals in an uptrend?
Its uptrend has stalled. Ironwood Pharmaceuticals is in Stage 3, the topping phase that follows an advance. It trades 10.9% below its 200-day average, which is rising.
How far is Ironwood Pharmaceuticals from its 52-week high?
Ironwood Pharmaceuticals closed at $3.57 on Oct 22, 2026, 33.8% below its 52-week high of $5.39. Its 52-week low is $1.50.
How has Ironwood Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Ironwood Pharmaceuticals is up 128.8% over the past year and down 16.4% so far in 2026.
Which sector and industry is Ironwood Pharmaceuticals in?
Ironwood Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.